Lisata Therapeutics Inc. (LSTA): Utang marang Ekuitas

Lisata Therapeutics (LSTA) price characteristics demonstrate a debt-to-equity ratio of 0.00, while the company develops treatments for dense neoplasms in US laboratories. The startup is currently expanding its market presence, aiming to move its lead drug candidate into final-stage testing. Business success relies on improving drug tissue penetration and the synergy between the CendR system and chemotherapy.

For Lisata Therapeutics (LSTA), which is scaling its oncology drug delivery platform, this indicator determines the extent to which business development depends on external borrowings relative to equity. By analyzing the total debt-to-equity ratio, an investor assesses financial leverage and default risk, which is critical for a biotech startup during costly international clinical trials.